VACCELERATE - European Corona Vaccine Trial Accelerator Platform


VACCELERATE aims to accelerate phase 2 & 3 COVID-19 vaccine trials. It is part of the European Commission “HERA incubator” program and it involves 29 partners both from EU-member states and EU-associated countries. VACCELERATE brings together different stakeholders involved in vaccine development across the EU to develop a platform for trial design and conduct. Its end goal is to develop a vaccine clinical trial network for the COVID-19 pandemic as well as to serve as point of reference for future emerging infectious diseases by playing a pivotal role in strengthening the vaccine development capacities of Europe.

VACCELERATE is 3-year project. It started in February 2021 and will terminate in February 2024. It has received funding from the European Union's Horizon 2020 programme (Grant Agreement no. 101037867).

CLEO is the National Coordinator for Greece, thereby acting as an ambassador of VACCELERATE and serving as the country’s point of contact. In this role, CLEO maps clinical trial sites and laboratories in Greece, while also adapting all VACCELERATE activities to national requirements and identifying the needs for education and capacity building across Greek vaccine trial sites.

CLEO is also the lead partner for the capacity mapping analysis of pediatric vaccine clinical trial sites across Europe. The main objectives are to map and analyze the capacity of these sites, collect and analyze past performance and define minimum quality standards with a focus on the standardization and harmonization of pediatric COVID-19 vaccine research, in order to develop or inform pediatric-specific vaccination programs future.

CLEO is also a co-lead and contributor to VACCELERATE research activities focused on understanding volunteer COVID-19 vaccine trial participation, especially among under-represented and hard-to-reach groups across Europe and EU-associated countries.

Relavant Links:

Clinical trial sites interested in conducting COVID-19 vaccine studies can register to the EUVAP Platform,
For individuals interested in signing up to upcoming COVID-19 vaccination studies,
Contact us: This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more about VACCELERATE,